論文 - 詳細
| RRC ID | 64038 |
|---|---|
| 著者 | Yamanaka R, Zullo SA, Ramsey J, Onodera M, Tanaka R, Blaese M, Xanthopoulos KG. |
| タイトル | Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. |
| ジャーナル | Cancer Gene Ther |
| Abstract |
Antiangiogenic therapy using Semliki Forest virus (SFV) carrying Endostatin gene for malignant brain tumor was investigated to improve the therapeutic efficacy. The efficiency of SFV-mediated gene delivery was first evaluated for B 16 cells and compared with the efficiency in cells of endothelial origin (HMVECs). HMVECs are more susceptible to SFV infection than B 16 cells. For the in vivo treatment model, phosphate-buffered saline, SFV-LacZ, retrovirus vector GCsap-Endostatin, and SFV-Endostatin were injected to mice bearing B 16 brain tumors. A very significant inhibition of tumor growth was observed in the group that had been treated with SFV-Endostatin. A marked reduction of intratumoral vascularization was seen in the tumor sections from the SFV-Endostatin group compared with tumor sections from the SFV-LacZ or GCsap-Endostatin groups. Moreover, at day 7 after intravenous administration of SFV-Endostatin, the serum level of endostatin was augmented more than 3-fold compared to that after intravenous administration of GCsap-Endostatin. The results indicated that treatment with SFV-Endostatin inhibited the angiogenesis with established tumors. Gene therapy with Endostatin delivered via SFV may be a candidate for the development of new therapy for brain tumors. |
| 巻・号 | 8(10) |
| ページ | 796-802 |
| 公開日 | 2001-10-1 |
| DOI | 10.1038/sj.cgt.7700367 |
| PMID | 11687903 |
| MeSH | Animals Brain Neoplasms / blood supply Brain Neoplasms / therapy* Brain Neoplasms / virology Cells, Cultured Collagen / blood Collagen / genetics* Endostatins Endothelium, Vascular / metabolism* Endothelium, Vascular / virology Female Gene Expression Gene Transfer Techniques Genetic Therapy / methods* Genetic Vectors / administration & dosage Humans Melanoma, Experimental / blood supply Melanoma, Experimental / therapy* Melanoma, Experimental / virology Mice Mice, Inbred C57BL Mice, Nude Neovascularization, Pathologic / therapy* Peptide Fragments / blood Peptide Fragments / genetics* Reverse Transcriptase Polymerase Chain Reaction Semliki forest virus / physiology* Survival Rate |
| IF | 4.534 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | B16 |